Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bug

Showing results (251-260 of 319) with videos related to

Pageof 32
Sort By:
Bone Marrow Transplantation|October 7, 2022
Correction to: Impact of conditioning regimen intensity on outcomes of second allogeneic hematopoietic cell transplantation for secondary acute myelogenous leukemiaArnon Nagler, Christophe Peczynski, Bhagirathbhai Dholaria, et al.
Bone Marrow Transplantation|December 20, 2024
Comparison of fludarabine/melphalan (FM140) with fludarabine/melphalan/BCNU (FBM110) in patients with relapsed/refractory AML undergoing allogeneic hematopoietic cell transplantation - a registry study on behalf of the EBMT Acute Leukemia Working PartyJesús Duque-Afonso, Jürgen Finke, Maud Ngoya, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 19, 2019
Biology-Driven Approaches to Prevent and Treat Relapse of Myeloid Neoplasia after Allogeneic Hematopoietic Stem Cell TransplantationRobert Zeiser, Dietrich W Beelen, Wolfgang Bethge, et al.
Annals of Hematology|April 5, 2017
Peripheral blood cytogenetics allows treatment monitoring and early identification of treatment failure to lenalidomide in MDS patients: results of the LE-MON-5 trialFriederike Braulke, Xenia Schulz, Ulrich Germing, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 20, 2021
Comparison Between 5-Azacytidine Treatment and Allogeneic Stem-Cell Transplantation in Elderly Patients With Advanced MDS According to Donor Availability (VidazaAllo Study)Nicolaus Kröger, Katja Sockel, Christine Wolschke, et al.
Bone Marrow Transplantation|July 30, 2020
Measurable residual disease (MRD) testing for acute leukemia in EBMT transplant centers: a survey on behalf of the ALWP of the EBMTArnon Nagler, Frédéric Baron, Myriam Labopin, et al.
American Journal of Hematology|December 6, 2025
Non-T-Depleted Haploidentical Transplantation Compared to Allogeneic Transplantation From Matched Siblings or Unrelated Donors in Patients With Secondary AML in First Complete Remission: A Study From the ALWP/EBMTArnon Nagler, Sarah Kayser, Allain Thibeault Ferhat, et al.
European Journal of Haematology|June 3, 2025
Sensitization of Non-M3 Acute Myeloid Leukemia Blasts to All-Trans Retinoic Acid by the LSD1 Inhibitor Tranylcypromine: TRANSATRA Phase I StudyMichael Kruszewski, Claudia Schmoor, Tobias Berg, et al.
BMC Bioinformatics|May 12, 2007
Advancing translational research with the Semantic WebAlan Ruttenberg, Tim Clark, William Bug, et al.
Cancer|May 25, 2022
Additional cytogenetic features determine outcome in patients allografted for TP53 mutant acute myeloid leukemiaJustin Loke, Myriam Labopin, Charles Craddock, et al.
Pageof 32

Showing results (251-260 of 319) with videos related to

Sort By:
Pageof 32
Bone Marrow Transplantation|October 7, 2022
Correction to: Impact of conditioning regimen intensity on outcomes of second allogeneic hematopoietic cell transplantation for secondary acute myelogenous leukemiaArnon Nagler, Christophe Peczynski, Bhagirathbhai Dholaria, et al.
Bone Marrow Transplantation|December 20, 2024
Comparison of fludarabine/melphalan (FM140) with fludarabine/melphalan/BCNU (FBM110) in patients with relapsed/refractory AML undergoing allogeneic hematopoietic cell transplantation - a registry study on behalf of the EBMT Acute Leukemia Working PartyJesús Duque-Afonso, Jürgen Finke, Maud Ngoya, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 19, 2019
Biology-Driven Approaches to Prevent and Treat Relapse of Myeloid Neoplasia after Allogeneic Hematopoietic Stem Cell TransplantationRobert Zeiser, Dietrich W Beelen, Wolfgang Bethge, et al.
Annals of Hematology|April 5, 2017
Peripheral blood cytogenetics allows treatment monitoring and early identification of treatment failure to lenalidomide in MDS patients: results of the LE-MON-5 trialFriederike Braulke, Xenia Schulz, Ulrich Germing, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 20, 2021
Comparison Between 5-Azacytidine Treatment and Allogeneic Stem-Cell Transplantation in Elderly Patients With Advanced MDS According to Donor Availability (VidazaAllo Study)Nicolaus Kröger, Katja Sockel, Christine Wolschke, et al.
Bone Marrow Transplantation|July 30, 2020
Measurable residual disease (MRD) testing for acute leukemia in EBMT transplant centers: a survey on behalf of the ALWP of the EBMTArnon Nagler, Frédéric Baron, Myriam Labopin, et al.
American Journal of Hematology|December 6, 2025
Non-T-Depleted Haploidentical Transplantation Compared to Allogeneic Transplantation From Matched Siblings or Unrelated Donors in Patients With Secondary AML in First Complete Remission: A Study From the ALWP/EBMTArnon Nagler, Sarah Kayser, Allain Thibeault Ferhat, et al.
European Journal of Haematology|June 3, 2025
Sensitization of Non-M3 Acute Myeloid Leukemia Blasts to All-Trans Retinoic Acid by the LSD1 Inhibitor Tranylcypromine: TRANSATRA Phase I StudyMichael Kruszewski, Claudia Schmoor, Tobias Berg, et al.
BMC Bioinformatics|May 12, 2007
Advancing translational research with the Semantic WebAlan Ruttenberg, Tim Clark, William Bug, et al.
Cancer|May 25, 2022
Additional cytogenetic features determine outcome in patients allografted for TP53 mutant acute myeloid leukemiaJustin Loke, Myriam Labopin, Charles Craddock, et al.
Pageof 32